BioLife Solutions, Inc. (NASDAQ:BLFS – Get Free Report) EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total transaction of $239,000.00. Following the sale, the executive vice president now directly owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
BioLife Solutions Price Performance
NASDAQ BLFS opened at $25.77 on Friday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -18.15 and a beta of 1.87. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. The stock’s fifty day moving average price is $24.17 and its 200 day moving average price is $20.94. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $26.73.
BioLife Solutions (NASDAQ:BLFS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. BioLife Solutions had a negative return on equity of 10.75% and a negative net margin of 59.88%. The business had revenue of $28.33 million for the quarter, compared to analyst estimates of $23.80 million. As a group, equities research analysts forecast that BioLife Solutions, Inc. will post -0.36 earnings per share for the current year.
Hedge Funds Weigh In On BioLife Solutions
Analysts Set New Price Targets
Several analysts have recently commented on the company. Northland Securities increased their price objective on BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Craig Hallum increased their price target on BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Finally, TD Cowen boosted their price target on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.20.
Check Out Our Latest Stock Analysis on BLFS
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading
- Five stocks we like better than BioLife Solutions
- Comparing and Trading High PE Ratio Stocks
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Why Invest in 5G? How to Invest in 5G Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- What Makes a Stock a Good Dividend Stock?
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.